This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Niveles óptimos de este último funcionan como protectores cardíacos. Para alcanzar valores adecuados de omega 3 que cuiden nuestro corazón, se recomienda consumir al menos dos porciones de pescado a ...

Panaji (Goa)[India], October 19 (ANI): The 24th edition of National Para Swimming Championship started on October 19 and will continue till October 22 at the Olympic Swimming Pool in Panaji, Goa. The ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...

Esta afirmación, siguiendo la misma fuente, brinda objetivos prometedores para futuras investigaciones de nuevas sustancias bioactivas y fitoterapia y que brinden mayor evidencia científica.

Una gran parte de lo que consumimos contiene magnesio e incluso en infinidad de notas de salud o gastronomía se destaca que tal o cual alimento contiene más o menos mineral. Sin embargo, la ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

NEW YORK – The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on Friday said it would recommend marketing authorization for Novartis' CDK4/6 inhibitor Kisqali ...